



LAHIVE
&
COCKFIELD
LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DiROCCO TYNER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA
VINCENT P. LOCCISANO
JAMES M. McKENZIE

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DiGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
JAMES H. VELEMA
W. ELANA WANG
CYNTHIA M. GILBERT

* Admitted in TX only
** Admitted in CT only

November 26, 2004

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/010,942
For: *HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID
PEPTIDE*
Inventors: Basi, Guriq, *et al.*
Filed: December 6, 2001
Our Ref. No.: ELN-002

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO SB/08B;
3. Copies of references cited in PTO Form PTO/SB/08A (223); and
4. A Return Postcard.

Please charge any necessary fees in connection with the enclosed statement to our
Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the
United States Postal Service as first class mail in an envelope
addressed to: MS Amendment, Commissioner for Patents, P.O.
Box 1450, Alexandria, Virginia 22313-1450 on:

November 26, 2004


Date

Debra J. Milasincic, Esq., Reg. No. 46,931

Respectfully submitted,
LAHIVE & COCKFIELD LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re the application of: Basi, Guriq, *et al.*

Serial No.: 10/010,942

Filed: December 6, 2001

For: *HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE*

Attorney Docket No.: ELN-002

Group Art Unit: 1647

Examiner: Nichols, Christopher J.

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

November 26, 2004

Date of Signature and of Mail Deposit

By:

Debra J. Milasincic, Esq.

Registration No. 46,931

Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their Attorney are aware of the following additional publications, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed

per se as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


A handwritten signature in black ink, appearing to read 'Debra J. Milasincic', is written over a horizontal line. The signature is fluid and cursive, with a large loop at the beginning and a long, sweeping tail.

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: November 26, 2004

AEM/DJM/AWZ/rl
Enclosures



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	1	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	306	6,417,178 B1	07-09-2002	Klunk, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	324	WO 00/72870 A1	12-07-2000	Neuralab Ltd.		
	331	WO 99/06545	11-02-1999	Max Planck Gesellschaft		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	327	Cameron. "Recent Advances in Transgenic Technology," <i>Molecular Biotechnology</i> . 1997; 7:253-65.			
	328	Feldstein, <i>et al.</i> "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing." <i>Alzheimer's and Parkinson's Diseases</i> . 1995; Hanin, <i>et al.</i> Ed., pp 401-9, Plenum Press, New York.			
	329	Niemann. "Transgenic farm animals get off the ground." <i>Transgenic Research</i> . 1998; 7:73-5.			
	330	Sigmund. "Viewpoint: Are Studies in Genetically Altered Mice Out of Control." <i>Arterioscler Thromb Vasc Biol</i> . 2000; 20:1425-9.			
	332	Chen, <i>et al.</i> "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice." <i>Progress in Brain Research</i> . Van Leeuwen, <i>et al.</i> Eds, 1998; 117:327-37.			
	333	Conway, <i>et al.</i> "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy." <i>PNAS</i> ., 2000; 97(2):571-6.			
	334	Jobling and Holmes, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis." <i>Molecular Microbiology</i> . 1991; 5(7):1755-67.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	2	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	342	2002/0009445 A1	01-24-2002	Du, <i>et al.</i>	
	345	2002/0077288 A1	06-21-2001	Frangione	
	346	5,935,927	08-10-1999	Vitek, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	341	WO 02/03911 A2	01-17-2002	Lannfelt, L.		
	343	EP 1172378 A1	01-16-2002	Dodel, Dr. R., <i>et al.</i>		
	344	WO 01/90182 A2	11-29-2001	University of New York		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	335	Masliah, <i>et al.</i> "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease." <i>PNAS</i> . 2001; 98(21):12245-50.			
	336	Perutz, <i>et al.</i> "Amyloid fibers are water-filled nanotubes." <i>PNAS</i> . 2002; 99(8):5591-5.			
	337	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era." <i>Trends in Biotech.</i> 2000; 18(1):34-9.			
	338	Stein, <i>et al.</i> "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways." <i>The Journal of Neuroscience</i> . 2002 Sep 1; 22(17):7380-8.			
	339	Tennent, <i>et al.</i> "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis." <i>PNAS</i> . 1995; 92:4299-303.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	3	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	353	5,824,322	10-20-1998	Balasubramanian	
	356	5,622,701	04-22-1997	Berg	
	357	5,776,468 B1	07-07-1998	Hauser, <i>et al.</i>	
	358	5,583,112 B2	12-10-1996	Kensil, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	348	WO 01/77167 A2	10-18-2001	Univ Tennessee Res Corp		
	351	WO 02/34878 A2	05-02-2002	Yeda Resrstvh & Development Co. Ltd.		
	352	WO 02/34777 A1	05-02-2002	Chiesi Farma SPA		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	347	Jorbeck, <i>et al.</i> "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis." <i>Infection and Immunity</i> . 1981 May; 497-502.	
	349	Check. "Battle of the Mind." <i>Nature</i> . 2002 Mar; 422:370-2.	
	350	Nicoll, <i>et al.</i> "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report." <i>Nature Medicine</i> . 2003 Apr; 9(4):448-52.	
	354	Mutschler, <i>et al.</i> "Drug Actions: Basic Principles and Therapeutic Aspects." 1995; 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.	
	355	Munson ed. "Principals of Pharmacology: Basic Concepts & Clinical Applications." 1995; 47-8, Chapman & Hall, New York, New York.	
	359	Munch, <i>et al.</i> "Potential neurotoxic inflammatory response to A β vaccination in humans" <i>J. Neural Transm.</i> 2002; 109:1081-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	4	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	360	2003/0073655 A1	04-17-2003	Chain	
	362	2002/0094335 A1	07-18-2002	Chalifour, <i>et al.</i>	
	365	2002/0133001 A1	09-19-2002	Gefter, <i>et al.</i>	
	366	2002/0187157 A1	12-12-2002	Jensen, <i>et al.</i>	
	370	2003/0068325 A1	04-10-2003	Wang	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	361	Su, <i>et al.</i> "Intravascular infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage." <i>Brain Research</i> . 1999; 818:105-7.		
	363	Dodart. "Immunotherapy for Alzheimer's disease: will vaccination work?" <i>Trends in Molecular Medicine</i> . 2003; 9(3):85-7.		
	364	Furlan, <i>et al.</i> "Vaccination with amyloid- β peptide induces autoimmune encephalomyelitis in C57/BL6 mice." <i>Brain</i> . 2003; 126:285-91.		
	367	Monsonogo, <i>et al.</i> "Immune hyporesponsiveness to amyloid β -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease." <i>PNAS</i> . 2001; 98(18):10273-8.		
	368	Sipe. "Amyloidosis." <i>Annu. Rev. Biochem.</i> 1992; 61:947-75.		
	369	Spooner, <i>et al.</i> "The generation and characterization of potentially therapeutic A β antibodies in mice: differences according to strain and immunization protocol." <i>Vaccine</i> . 2002; 21:290-7.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	5	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	373	5,721,130	02-24-1998	Seubert, <i>et al.</i>	
	376	2002/0086847 A1	07-04-2002	Chain	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	378	2002/0197258 A1	12-26-2003	Ghanbari, <i>et al.</i>	
	379	2002/0132268 A1	09-19-2002	Chang, <i>et al.</i>	
	380	5,750,361	05-12-1998	Prusiner, <i>et al.</i>	
	381	2001/0021769 A1	09-13-2001	Prusiner	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	371	Johnstone, <i>et al.</i> "Nuclear and Cytoplasmic Localization of the β -Amyloid Peptide (1-43) in Transfected 293 Cells." <i>Biochemical and Biophysical Research Communications</i> . 1996; 220:710-18.		
	372	Akiyama, <i>et al.</i> "Occurrence of the Diffuse Amyloid β -Protein ($A\beta$) Deposits With Numerous $A\beta$ -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease." <i>Glia</i> . 1999; 25:324-31.		
	374	Jakes, <i>et al.</i> "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease." <i>Alzheimer Disease and Associated Disorders</i> . 1995; 9(1):47-51, Raven Press, Ltd., New York.		
	375	Tsuzuki, <i>et al.</i> "Amyloid β protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for $A\beta$ 40 and $A\beta$ 42: immunohistochemical evidence for amyloid β protein." <i>Neuroscience Letters</i> . 1995; 2002:77-80.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	6	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	382	5,846,533	12-08-1998	Prusiner	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	383	WO 97/10505 A1	03-20-1997	University of California		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	384	Sigurdsson, <i>et al.</i> "Immunization Delays the Onset of Prion Disease in Mice." <i>American Journal of Pathology</i> , 2002; 161:13-17.		
	385	Wisniewski, <i>et al.</i> "Therapeutics in Alzheimer's and Prion Diseases." <i>Biochemical Society Transactions</i> . 2002; 30(4):-574-87.		
	386	Frautschy, <i>et al.</i> "Effects of injected Alzheimer β -amyloid cores in rat brain." <i>PNAS</i> . 1991; 88:8362-6.		
	387	Weldon, <i>et al.</i> "Neurotoxicity of A β Peptide: Confocal Imaging of Cellular Changes Induced by -Amyloid in Rat CNS <i>In Vivo</i> ." <i>Society for Neuroscience Abstracts</i> . 1996; 22(Part 1).		
	388	Goldfarb, <i>et al.</i> "The Transmissible Spongiform Encephalopathies." <i>Ann. Rev. Med.</i> 1995; 46:57-65.		
	389	Kovacs, <i>et al.</i> "Mutations of the Prion Protein Gene Phenotypic Spectrum." <i>J. Neurol.</i> 2002; 249:1567-82.		
	390	Diomede, <i>et al.</i> "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes." <i>Biochem. J.</i> 1996; 320:563-70.		
	391	Aguzzi, <i>et al.</i> "Prion research: the next frontiers." <i>Nature</i> . 1997; 389:795-8.		
	392	Tal, <i>et al.</i> "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice." <i>Journal of Neuroscience Research</i> . 2003; 71:286-90.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/010,942
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	7	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	395	2002/0160394 A1	10-31-2002	Wu	
	401	6,284,533 B1	09-04-2001	Thomas	
	402	4,713,366	12-15-1987	Stevens	
	403	5,464,823	11-07-1995	Lehrer, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	393	Akiyama, et al. "Inflammation and Alzheimer's disease." <i>Neurobiology of Aging</i> . 2000; 21:383-421.	
	394	Prusiner, et al. "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies." <i>PNAS</i> . 1993; 90:10608-12.	
	396	Sigurdsson, et al. "Anti-priori antibodies for prophylaxis following prion exposure in mice." <i>Neurosciences Letters</i> . 2003; 336:185-7.	
	397	Goldsteins, et al. "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants." <i>PNAS</i> . 1999; 96:3108-13.	
	398	Palha, et al. "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy." <i>J. Mol. Med</i> . 2001; 7:703-7.	
	399	Tan, et al. "Amyloidosis." <i>Histopathology</i> . 1994; 25:403-14.	
	400	Sigurdsson, et al. "A safer vaccine for Alzheimer's disease?" <i>Neurobiology of Aging</i> . 2002; 23:1001-8.	
	404	Benjamini and Leskowitz, from <i>IMMUNOLOGY A Short Course</i> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	8	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	405	6,399,314 B1	06-04-2002	Krishnamurthy	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	406	Pan, <i>et al.</i> "Antibodies to β -Amyloid Decrease the Blood-to-Brain Transfer of β -Amyloid Peptide." <i>Exp. Biol. Med.</i> 2002; 227(8):609-15.	
	407	Eck, <i>et al.</i> <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , 1996; Chapter 5, pages 77-101.	
	408	Marshall. "Gene Therapy's Growing Pains." <i>Science</i> . 1995; 269:1050-55.	
	409	Orkin, <i>et al.</i> <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995.	
	410	Verma, <i>et al.</i> "Gene therapy - promises, problems and prospects." <i>Nature</i> . 1997; 389:239-42.	
	411	Solomon, <i>et al.</i> "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility" from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher <i>et al.</i> , Plenum Press, New York, pages 205-11 (1995).	
	412	Das, <i>et al.</i> "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out-Mice." <i>J. Neuroscience</i> . 2003; 23(24):8532-8.	
	413	Holtzman, <i>et al.</i> "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease." <i>Advanced Drug Delivery Reviews</i> . 2002; 54:1603-13.	
	414	Schenk. "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning." <i>Nature Reviews</i> . 2002; 3:824-8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	9	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	415	2003/0166558 A1	09-04-2003	Frangione, <i>et al.</i>	
	416	6,303,567 B1	10-16-2001	Findeis, <i>et al.</i>	
	417	5,985,242	11-16-1999	Findeis, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	418	Bork. "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle." <i>Genome Research</i> . 2000; 10:398-400.		
	419	Bork, <i>et al.</i> "Go hunting in sequence databases but watch out for the traps." <i>Trends in Genetics</i> . 1996; 12(10):425-7.		
	420	Brenner. "Errors in genome annotation." <i>Trends in Genetics</i> . 1999; 15(4):132-3.		
	421	Castillo, <i>et al.</i> "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology." <i>Diabete & Metabolisme (Paris)</i> . 1995; 21:3-25.		
	422	Doerks, <i>et al.</i> "Protein annotation: detective work for function prediction." <i>Trends in Genetics</i> . 1998; 14(6):248-50.		
	423	Fonseca, <i>et al.</i> "The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age." <i>Experimental Neurology</i> . 1999; 157(2):277-88.		
	424	Goldsby, <i>et al.</i> "Vaccines," Chapter 18 from <i>Immunology, 4th Edition</i> , W.H. Freeman and Company, New York, pages 449-465.		
	425	Ngo, <i>et al.</i> "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz <i>et al.</i> , eds., Birkhauser Boston (1994).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	10	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	431	2003/0165496 A1	09-04-2003	Basi, <i>et al.</i>	
	432	6,562,341 B2	05-13-2003	Prusiner, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	433	WO 03/020212	03-13-2003	Mayo Foundation for Medical Education and Research		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	426	Singh, K.S. "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease." <i>Gerontology</i> . 1997; 43:79-94.	
	427	Smith, <i>et al.</i> "The challenges of genome sequence annotation or 'The devil is in the details.'" <i>Nature Biotechnology</i> . 1997; 15:1222-3.	
	428	Velazquez, <i>et al.</i> "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis." <i>Nature Medicine</i> . 1997; 3(1):77-9.	
	429	Wells. "Additivity of Mutational Effects in Proteins." <i>Biochemistry</i> . 1990; 29(37):8509-17.	
	430	Yang, <i>et al.</i> "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214 th National Meeting (1997).	
	434	Kelly. "Alternative conformations of amyloidogenic proteins govern their behavior." <i>Current Opinion in Structural Biology</i> . 1996; 6:11-17.	
	435	Stern, <i>et al.</i> "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood." <i>FEBS Letters</i> . 1990; 264(1):43-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	11	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	440	2003/0068316 A1	04-10-2003	Klein, <i>et al.</i>	
	442	6,713,450 B2	03-30-2004	Frangione, <i>et al.</i>	
	444	2004/0043418 A1	03-04-2004	Holtzman, <i>et al.</i>	
	445	5,854,215	12-29-1998	Findeis, <i>et al.</i>	
	446	5,817,626	10-06-1998	Findeis, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	441	WO 03/104437 A2	12-18-2003	Northwestern University		
	443	WO 03/074081 A1	09-12-2003	Mindset Biopharmaceuticals USA		
	447	WO 03/051374 A2	06-26-2003	New York State Office of MENTA		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	436	Dickson, <i>et al.</i> "Neuroimmunology of Alzheimer's disease: a conference report." <i>Neurobiology of Aging</i> . 1992; 13(6):793-8, abstract only.	
	437	Persson, <i>et al.</i> "IgG subclass-associated affinity differences of specific antibodies in humans." <i>J. Immunology</i> . 1988; 140(11):3875-9, abstract only.	
	438	Singh, V.K. "Studies of neuroimmune markers in Alzheimer's disease." <i>Mol. Neurobiology</i> . 1994; 9(1-3):73-81, abstract only.	
	439	Nalbantoglu. "Beta-amyloid protein in Alzheimer's disease." <i>Can. J. Neurol. Sci.</i> 1991; 18(3 suppl.):424-7, abstract only.	
	448	Andrew, <i>et al.</i> <i>Current Protocols in Immunology</i> . 1997; 2.7.1-2.9.8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	12	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	451	5,766,846	06-16-1998	Schlossmacher, <i>et al.</i>	
	452	6,218,506 B1	04-17-2001	Krafft, <i>et al.</i>	
	453	2002/0058267 A1	05-16-2002	Ozenberger, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	450	WO 01/18169 A3	03-15-2001	Ramot University		
	454	WO 98/33815 A1	08-06-1998	Acumen Pharmaceuticals, Inc.		
	455	WO 01/10900 A2	02-15-2001	University of Southern California, <i>et al.</i>		
	456	WO 02/021141 A2	03-14-2002	Aventis Pharma SA, <i>et al.</i>		
	457	WO 02/406237 A1	06-13-2002	Neuralab Ltd., <i>et al.</i>		
	458	WO 02/060481 A1	08-08-2002	Milkhaus Lab, Inc.		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	449	Johnson-Wood, <i>et al.</i> "Amyloid precursor protein processing and A β ₄₂ deposition in a transgenic mouse model of Alzheimer disease." <i>PNAS</i> . 1997; 94:1550-5.	
	459	Levitt. "Molecular dynamics of native protein." <i>J. Mol Biol.</i> 1983; 168:595-620.	
	460	Queen, <i>et al.</i> "A humanized antibody that binds to the interleukin 2 receptor." <i>Proc Natl Acad Sci USA</i> . 1989; 86:10029-33.	
	461	Burdick, <i>et al.</i> "Assembly and aggregation properties of synthetic Alzheimer's A4 β amyloid peptide antigens." <i>J Biol Chme</i> . 1992; 267:546-55.	
	462	Co, <i>et al.</i> "Chimeric and humanized antibodies with specificity for the CD33 antigen." <i>J Immunol</i> . 1992; 148:1149-54.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	13	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	463	Ghiso, <i>et al.</i> "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease." <i>Biochem J.</i> 1992; 282 (Pt 2):517-22.	
	464	Flood, <i>et al.</i> "An amyloid β -Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures." <i>Brain Res.</i> 1994; 663(2):271-6.	
	465	Koudinov, <i>et al.</i> "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma." <i>Biochem & Biophys Res Comm.</i> 1994; 205:1164-71.	
	466	Schwarzman, <i>et al.</i> "Transthyretin sequesters amyloid β protein and prevents amyloid formation." <i>Proc Natl Acad Sci.</i> 1994; 91:8368-72.	
	467	Tabaton, <i>et al.</i> "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid." <i>Biochem and Biophys Res Comm.</i> 1994; 200(3):1598-1603.	
	468	Wisniewski, <i>et al.</i> "Alzheimer's disease and soluble A beta." <i>Neurobiol Aging.</i> 1994; 15(2):143-52, Review.	
	469	DeMattos, <i>et al.</i> "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease ³ ." <i>Proc Natl Acad Sci USA.</i> 98(15):8850-55.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	14	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	470	Giulian, <i>et al.</i> "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia." <i>J Neurosci.</i> 1996; 16 (19):6021-37.	
	471	Hilbich, <i>et al.</i> "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides." <i>J. Mol. Biol.</i> 1992; 228:460-73.	
	472	Teller, <i>et al.</i> "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome." <i>Nature Medicine.</i> 1996; 2(1):93-95.	
	473	Hilbich, <i>et al.</i> "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease." <i>J. Mol. Biol.</i> 1991; 218:149-63.	
	474	Winter, <i>et al.</i> "Humanized antibodies." <i>Immunology Today.</i> 1996; 14(6):243-6.	
	475	El-Agnaf, <i>et al.</i> "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide." <i>Eur J Biochem.</i> 1998; 256(3):560-9.	
	476	He, <i>et al.</i> "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin." <i>J Immunol.</i> 1998; 160:1029-35.	
	477	Lambert, <i>et al.</i> "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins." <i>Proc Natl Acad Sci.</i> 1998; 95:6448-53.	
	478	Kuo, <i>et al.</i> "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease." <i>Biochem Biophys Res Commun.</i> 1999; 257(3):787- 91.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	15	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	479	McLean, <i>et al.</i> "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease." <i>Amer Neurological Assoc.</i> 1999; 46:860-6.	
	480	Wang, <i>et al.</i> "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging." <i>Experimental Neurology.</i> 1999; 158:328-37.	
	481	Levy, <i>et al.</i> "Immunization for Alzheimer's disease: A shot in the arm or a whiff?" <i>American Neurological Assoc.</i> 2000; 48:553-4.	
	482	Naslund, <i>et al.</i> "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline." <i>J Am Med Assoc.</i> 2000; 283:1571.	
	483	Zlokovic, <i>et al.</i> "Clearance of amyloid β -peptide from brain: transport or metabolism?" <i>Nature Medicine.</i> 2000; 6(7):718-19.	
	484	Arendiash, <i>et al.</i> "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory." <i>DNA and Cell Biology.</i> 2001; 20(11):737-44.	
	485	Bacskai, <i>et al.</i> "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy." <i>Nature Medicine.</i> 2001; 7(3): 369-72.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	16	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	486	Dickey, <i>et al.</i> "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide." <i>DNA and Cell Biology</i> . 2001; 20(11):723-9.	
	487	Haass, <i>et al.</i> "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?" <i>Nature Neuroscience</i> . 2001; 4(9):859-60.	
	488	Klein, <i>et al.</i> "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?" <i>Trends in Neurosciences</i> . 2001; 24(4):219-24.	
	489	Lambert, <i>et al.</i> "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies." <i>J Neurochem</i> . 2001; 79:595-605.	
	490	Lee, <i>et al.</i> "A β immunization: Moving A β peptide from brain to blood." <i>PNAS</i> . 2001; 98(16): 8931-2.	
	491	Poduslo, <i>et al.</i> "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease." <i>Neurobiol Dis</i> . 2001; 8(4): 555-67.	
	492	Town, <i>et al.</i> "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} ." <i>Neurosci Lett</i> . 2001; 307:101-4.	
	493	DeMattos, <i>et al.</i> "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease." <i>J Neurochem</i> . 2002; 81:229-36.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	17	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	494	Kotilinek, <i>et al.</i> "Reversible memory loss in a mouse transgenic model of Alzheimer's disease." <i>J Neurosci.</i> 2002; 22(15):6331-5.	
	495	Wang, <i>et al.</i> "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus." <i>Brain Research.</i> 2002; 924:133-40.	
	496	Strbak, <i>et al.</i> "Passive Immunization and Hypothalamic Peptide Secretion." <i>Neuroendocrinology.</i> 1993; 58:210-17.	
	497	Ragusi, <i>et al.</i> "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies." <i>J. Neurochem.</i> 1998; 70(5):2099-105.	
	498	Suo, <i>et al.</i> "Soluble Alzhelmers β -amyloid constricts the cerebral vasculature in vivo." <i>Neuroscience Letters.</i> 1998; 257:77-80.	
	499	Lue, <i>et al.</i> "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease." <i>Am. J. Pathol.</i> 1999; 155:853-62.	
	500	Tjemberg, <i>et al.</i> "A molecular model for Alzheimer amyloid β -peptide fibril formation." <i>J. Biol. Chem.</i> 1999; 274(18):12619-25.	
	501	Esler, <i>et al.</i> "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence." <i>Biochemistry/</i> 1996; 35:13914-21.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	18	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	502	Maggio, <i>et al.</i> "Brain Amyloid - A Physicochemical Perspective." <i>Brain Pathology</i> . 1996; 6:147-62.	
	503	Gorevic, <i>et al.</i> "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern." <i>Biochem. and Biophys. Res. Commun.</i> 1987; 147(2).	
	504	Balbach, <i>et al.</i> "Amyloid fibril formation by A β ₁₆₋₂₂ , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR." <i>Biochemistry</i> . 2000; 39:13748-59.	
	505	Simmons. "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ." <i>Molecular Pharmacology</i> . 1994; 45:373-9.	
	506	Wood, <i>et al.</i> "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4." <i>Biochemistry</i> . 1995; 34:724-30.	
	507	Xu, <i>et al.</i> "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease." <i>Mechanisms of Aging and Development</i> . 1997; 94:213-22.	
	508	Soto, <i>et al.</i> "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation." <i>J. Biol. Chem.</i> 1995; 270(7):3063-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	19	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	510	6,022,859	02-08-2000	Kiessling, <i>et al.</i>	
	511	6,331,440	12-18-2001	Nordstedt, <i>et al.</i>	
	512	5,891,991	04-06-1999	Wasco, <i>et al.</i>	
	513	5,514,548	05-07-1996	Krebber, <i>et al.</i>	
	514	5,470,951	11-28-1995	Roberts	
	515	5,652,334	07-29-1997	Roberts	
	516	6,261,569	07-17-2001	Comis, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	517	WO 94/05311 A1	03-17-1994	Deakin Research Ltd.		
	518	WO 95/23166 A1	08-31-1995	Deakin Research Ltd.		
	519	WO 00/26238 A2	05-11-2000	Imperial College Innovations Ltd.		
	520	WO 98/22120 A1	05-28-1998	University of Pennsylvania, <i>et al.</i>		
	521	WO 98/05350 A1	02-12-1998	Milkhaus Lab, Inc.		
	522	WO 00/20027 A2	04-13-2000	M&E Biotech AS		
	523	EP 752886 B1	01-28-1998	Mouritsen & Elsner AS		
	524	WO 95/05393 A2	02-23-1995	Morphosys Proteinoptimierung		
	525	WO 98/02462 A1	01-22-1998	Morphosys Proteinoptimierung		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	509	Cirrito, <i>et al.</i> "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details." <i>J. Clin. Invest.</i> 2003; 112:321-3.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Basi, Guriq
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	20	of	21	Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	526	WO 99/06587 A2	02-11-1999	Morphosys AG		
	527	WO 97/32017 A1	09-04-1997	Morphosys Proteinoptimierung		
	528	WO 97/08320 A1	03-06-1997	Morphosys AG		
	529	WO 00/68263 A2	11-16-2000	Neurochem, Inc.		
	530	WO 98/08868 A1	03-05-1998	Praecis Pharm., Inc.		
	531	WO 95/08999 A1	04-06-1995	City of Hope		
	532	WO 96/37621 A2	11-28-1996	Morphosys Proteinoptimierung		
	533	AU 707083	07-01-1999	Mouritsen & Elsner AS		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	534	Hock, <i>et al.</i> "Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease." <i>Neuron</i> . 2003; 38:542-54.		
	535	van Regenmortel, <i>et al.</i> "D-peptides as immunogens and diagnostic reagents." <i>Curr. Opin. Biotech.</i> 1998; 9(4):377-82.		
	536	Sela, <i>et al.</i> "Different roles of D-amino acids in immune phenomena." <i>FASEB J.</i> 1999; 11(6):449-56.		
	537	Tjernberg, <i>et al.</i> "Controlling amyloid beta-peptide fibril formation with protease-stable ligands." <i>J. Biol Chem.</i> 1997; 272(19):12601-5.		
	538	Flood, <i>et al.</i> "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein." <i>PNAS</i> . 1994; 91:380-4.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

